media Media
Healthcare Industry Media Coverage2017-09-13T20:18:16+00:00

Media Coverage

Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World

From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in the marketplace. So far, it’s more like a ripple, according to a study of neurologists’ prescribing patterns. “The recently approved therapies will initially be niched as later-line options,” predicted Virginia R. Schobel, MSc, nephrology franchise head at Spherix Global Insights... (read more).

June 5, 2020|

Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US

From: Ankylosing Spondylitis News By: Patricia Inacio, PhD.         According to Spherix Global Insights' survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread use for Cimzia...(read more).

May 18, 2020|

AbbVie Prompts Patients to ‘take on’ Arthritis in First Rinvoq DTC Ad

From: FiercePharma By: Beth Snyder Bulik           AbbVie Prompts Patients to 'take on' Arthritis in First Rinvoq DTC Ad While Xeljanz still enjoys support from rheums given the drug’s seven-year commercial history, docs indicated Rinvoq as the most preferred JAK if only one were to be prescribed, citing safety, efficacy and breadth of data all as key advantages over Xeljanz," Piper Jaffray analyst Christopher Raymond wrote...(read more).

March 2, 2020|
Go to Top